Bank of America reports 7% stake in CytomX

Bank of America Corporation filed a Schedule 13G reporting beneficial ownership of CytomX Therapeutics, Inc. common stock.

Rhea-AI Filing Summary

Bank of America Corporation filed a Schedule 13G reporting beneficial ownership of CytomX Therapeutics, Inc. common stock. It reports beneficial ownership of 15,134,689 shares, representing 7.0% of the outstanding common stock, based on 217,702,919 shares outstanding as reported by CytomX as of April 30, 2026.

Bank of America reports no sole voting or dispositive power. It has shared voting power over 15,133,689 shares and shared dispositive power over 15,134,689 shares through its wholly owned subsidiaries, including BofA Securities, Inc., Bank of America N.A., Merrill Lynch International, and Merrill Lynch Pierce Fenner & Smith, Inc.

Key Figures

Beneficially owned shares: 15,134,689 shares Percent of class: 7.0% Shares outstanding baseline: 217,702,919 shares +4 more

7 metrics

Beneficially owned shares 15,134,689 shares CytomX common stock beneficially owned by Bank of America Corporation

Percent of class 7.0% Portion of CytomX common stock class beneficially owned

Shares outstanding baseline 217,702,919 shares CytomX shares outstanding as of April 30, 2026, per Form 10-Q

Sole voting power 0 shares Shares of CytomX for which Bank of America has sole voting power

Shared voting power 15,133,689 shares Shares of CytomX for which Bank of America has shared voting power

Sole dispositive power 0 shares Shares of CytomX for which Bank of America has sole dispositive power

Shared dispositive power 15,134,689 shares Shares of CytomX for which Bank of America has shared dispositive power

Key Terms

beneficial ownership, dispositive power, parent holding company, broker dealer

4 terms

beneficial ownership financial

"Comment for : The beneficial ownership calculation relies on the 217,702,919 outstanding shares"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

dispositive power financial

"Shared Dispositive Power 15,134,689.00"

Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.

parent holding company financial

"If a parent holding company has filed this schedule, pursuant to (ii)(G)"

broker dealer financial

"a broker dealer registered under section 15 of the Act"

A broker-dealer is a firm or individual that helps people buy and sell stocks, bonds and other securities (acting as a broker) and may also trade those same securities with its own money (acting as a dealer). It matters to investors because broker-dealers execute trades, hold assets, provide access to markets and research, and can create conflicts of interest — like a market operator that also sells its own goods — so their costs, speed and trustworthiness directly affect investment outcomes.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What percentage of CytomX Therapeutics (CTMX) does Bank of America report owning?

Bank of America reports beneficial ownership of 7.0% of CytomX Therapeutics’ common stock, representing 15,134,689 shares. This percentage is based on 217,702,919 shares outstanding as of April 30, 2026, as reported by CytomX.

How many CytomX (CTMX) shares does Bank of America beneficially own?

Bank of America reports beneficial ownership of 15,134,689 shares of CytomX common stock. This stake corresponds to 7.0% of the class, calculated using CytomX’s reported 217,702,919 shares outstanding as of April 30, 2026.

Does Bank of America have sole or shared voting power over its CTMX shares?

Bank of America reports 0 shares with sole voting power and 15,133,689 shares with shared voting power in CytomX. The position is held through its wholly owned subsidiaries, which collectively exercise that shared voting authority.

What dispositive power does Bank of America report over CytomX (CTMX) shares?

Bank of America reports no sole dispositive power and shared dispositive power over 15,134,689 shares of CytomX common stock. These shares are held via subsidiaries including BofA Securities, Bank of America N.A., and Merrill Lynch entities.

Which Bank of America subsidiaries are involved in the reported CTMX holdings?

The reported CytomX holdings are attributed to Bank of America and its wholly owned subsidiaries: BofA Securities, Inc., Bank of America N.A., Merrill Lynch International, and Merrill Lynch Pierce Fenner & Smith, Inc..

What share count did Bank of America use to calculate its 7.0% CTMX stake?

The 7.0% ownership figure is based on 217,702,919 CytomX shares outstanding. This outstanding share count comes from CytomX’s Form 10-Q filed May 7, 2026, reporting totals as of April 30, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/03/2026 - 12:06 PM Accepted by SEC EDGAR 08/03/2026 - 12:05 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

CytomX Therapeutics, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

23284F105

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 23284F105

1

Names of Reporting Persons

BANK OF AMERICA CORP /DE/

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 15,133,689.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 15,134,689.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

15,134,689.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

7.0 %

12

Type of Reporting Person (See Instructions)

HC

Comment for Type of Reporting Person: The beneficial ownership calculation relies on the 217,702,919 outstanding shares disclosed in the Form 10-Q by the issuer on May 7, 2026, which reports share totals as of April 30, 2026.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: CytomX Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 151 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO, CALIFORNIA, 94080.
Item 2.
(a)	Name of person filing: BANK OF AMERICA CORP /DE/
(b)	Address or principal business office or, if none, residence: 100 N TRYON ST CHARLOTTE, NC 28255
(c)	Citizenship: Delaware
(d)	Title of class of securities: Common Stock
(e)	CUSIP Number(s): 23284F105
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 15,134,689.00
(b)	Percent of class: 7.0%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0.00
	(ii) Shared power to vote or to direct the vote: 15,133,689.00
	(iii) Sole power to dispose or to direct the disposition of: 0.00
	(iv) Shared power to dispose or to direct the disposition of: 15,134,689.00
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. This statement on Schedule 13G is being filed by Bank of America Corporation on behalf of itself and its wholly owned subsidiaries BofA Securities, Inc., a broker dealer registered under section 15 of the Act (15 U.S.C. 78o); Bank of America N.A., a bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c); Merrill Lynch International, a non-U.S. institution in accordance with section 240.13d-1(b)(1)(ii)(J); and Merrill Lynch Pierce Fenner & Smith, Inc., a broker dealer registered under section 15 of the Act (15 U.S.C. 78o).
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

BANK OF AMERICA CORP /DE/

Signature:	/s/ Monica Yako
Name/Title:	Authorized Signatory
Date:	08/03/2026